Welcome to our dedicated page for Neuropace news (Ticker: NPCE), a resource for investors and traders seeking the latest updates and insights on Neuropace stock.
NeuroPace, Inc. (Nasdaq: NPCE) is a medical device company based in Mountain View, California, focused on transforming the lives of people living with epilepsy through its brain-responsive RNS System. The NeuroPace news feed on Stock Titan highlights company announcements that relate to financial performance, clinical evidence, regulatory milestones, reimbursement developments, and technology progress in neuromodulation and AI-enabled epilepsy care.
Investors and clinicians following NPCE can find updates on quarterly and annual financial results, revenue trends driven by RNS System sales, and guidance for future periods. NeuroPace frequently reports on gross margin performance, operating expenses, and strategic decisions such as focusing organizational efforts on its differentiated RNS System and treating certain distribution activities as discontinued operations for reporting purposes.
The news flow also includes clinical and regulatory developments, such as preliminary data from the NAUTILUS trial in antiseizure-medication resistant idiopathic generalized epilepsy (IGE), which has shown substantial median reductions in generalized tonic-clonic seizures and a favorable safety profile. NeuroPace provides updates on its Premarket Approval Supplement submissions to the U.S. Food and Drug Administration (FDA) for expanded RNS System indications, Breakthrough Device Designation for IGE, and progress in pediatric and AI software programs.
Another important category of news involves reimbursement and policy. NeuroPace has announced favorable Medicare Physician Fee Schedule and Outpatient Prospective Payment System decisions that increase reimbursement for RNS System implantation and replacement procedures and maintain stable inpatient classifications, developments the company describes as supportive of neurosurgeon adoption and patient access.
In addition, the NPCE news stream features participation in major medical and investor conferences, including the American Epilepsy Society Annual Meeting and large healthcare investment conferences, where NeuroPace presents Post-Approval Study data, NAUTILUS results, and demonstrations of NeuroPace AI and SeizureID tools. Users who want to monitor how clinical evidence, reimbursement, and AI-enabled tools evolve around the RNS System can review and revisit this news page for the latest company-issued information and event updates.
Summary not available.
Summary not available.
NeuroPace, a medical device company based in Mountain View, California, is set to announce its financial results for the first quarter of 2023 on May 4, 2023. The report will be released after market close, followed by a conference call at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). The call will be accessible through a live and archived webcast on the company's website, ensuring replay availability for at least 90 days. NeuroPace specializes in innovative treatments for epilepsy, particularly with its RNS System, aimed at offering personalized, real-time solutions to patients suffering from drug-resistant epilepsy. This advanced platform represents a significant step forward in the care of patients with seizure disorders, promoting improved outcomes.
NeuroPace, a medical device company focused on improving the lives of individuals with epilepsy, announced participation in the 22nd Annual Needham Virtual Healthcare Conference. The presentation will take place on April 17, 2023, at 7:15 a.m. PT / 10:15 a.m. ET. A live webcast and an archived recording will be available on the company’s website. NeuroPace is renowned for its RNS System, a brain-responsive platform that delivers real-time treatment to help reduce or eliminate seizures. This innovative technology aims to enhance the standard of care for patients suffering from drug-resistant epilepsy and has potential applications for other brain disorders.
NeuroPace reported its fourth quarter and full-year financial results for 2022, highlighting a 16% increase in total revenue to $12.8 million compared to the previous year. Initial implant revenue rose 15% to $9.8 million, while revenue from DIXI Medical products contributed $1.6 million. However, the company saw a decline in replacement implant revenue to $1.4 million, down from $2.5 million year-over-year, which was anticipated. Gross margin for Q4 was 69%, a decrease from 73% the previous year. Full-year revenue was $45.5 million, a 1% growth, with a net loss of $47.1 million.
For 2023, NeuroPace projects revenue between $50 million and $52 million, driven by RNS System utilization.
NeuroPace, Inc. (Nasdaq: NPCE) announced it will report its financial results for the fourth quarter and full year of 2022 on March 2, 2023, after market close. The webcast of the conference call will begin at 1:30 p.m. PT / 4:30 p.m. ET, accessible on their website for live and archived listening.
The company focuses on innovative epilepsy treatment solutions, particularly with its RNS System, designed to provide personalized, brain-responsive therapy to patients experiencing drug-resistant epilepsy. NeuroPace aims to enhance care standards and patient outcomes in managing seizures.
NeuroPace, Inc. (Nasdaq: NPCE) reported preliminary, unaudited revenue for Q4 2022 at approximately $12.8 million, a 16% growth year-over-year. Initial implant revenue rose 15% to about $9.8 million, while replacement implant revenue declined 44% to $1.4 million. For the full year 2022, total revenue is estimated at $45.5 million, slightly up from $45.2 million in 2021. The company appointed Dr. Uri Geiger to its Board of Directors, enhancing leadership with his extensive financial and healthcare background.
MOUNTAIN VIEW, Calif., Dec. 21, 2022 - NeuroPace (Nasdaq: NPCE) announced participation in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco on January 12th, 2023, at 9:00 a.m. Pacific Time. A live webcast and archived recording of their presentation will be accessible on the company’s investor website. NeuroPace is dedicated to improving the lives of people with epilepsy through its innovative RNS System, the first brain-responsive platform for real-time treatment at the seizure source, potentially enhancing care for patients with drug-resistant epilepsy.
NeuroPace, Inc. (NASDAQ: NPCE) has commenced a feasibility study involving the treatment of the first patient with Lennox-Gastaut Syndrome (LGS) using its RNS® System. This system, previously effective for focal onset seizures, aims to evaluate brain-responsive neurostimulation for LGS, a severe epilepsy type. Funded by a $9.3 million NIH grant, the study spans six sites enrolling 20 patients. Current treatments show limited efficacy, highlighting the urgent need for innovative interventions in managing LGS.
NeuroPace, Inc. (Nasdaq: NPCE) reported third-quarter 2022 financial results, achieving $11.2 million in total revenue, an 8% increase year-over-year. Initial implant revenue reached $9.2 million, up 18% from the prior year. Despite a decline in replacement implant revenue, the company initiated the distribution of DIXI Medical’s stereo EEG products. Operating expenses rose to $18.2 million, leading to a net loss of $11.8 million. The company updated its 2022 revenue guidance to $44.5 million to $45.5 million, reflecting positive growth expectations.